Revolution Medicines RVMDBehind new cancer drugs
5.42 % of fund value
Biotech company that develops drugs for RAS-driven cancers, such as pancreatic cancer
LH LONGEVITY HEALTHCARE FUND
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
LHLONGEVITY invests through the master fund Tema Oncology ETF (CANC) 98.94%
This fundLHLONGEVITYThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Revolution Medicines RVMD5.42%
Merck & MRK4.78%Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per the issuer's fact sheet
Launched less than a year ago, so no 1-year rank yet
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| 1W | 2W | 1M | 3M | 6M | MAX |
|---|---|---|---|---|---|
| +0.72% | +1.09% | +2.42% | +3.44% | +9.69% | +12.30% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Full year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | +1.9 | +0.4 | +1.3 | +7.6 | −2.0 | +6.4 | −3.3 | +0.4 | −0.4 | · | +12.3* |
Largest drawdown in the selected period −11.95% Previous peak 25 Aug 2026 (NAV 12.0639) → Trough 14 Oct 2026 (NAV 10.6227) · Not back to the previous peak as of 3 Nov 2026
Currently −6.91% from the peak NAV of 12.0639 (25 Aug 2026)
Over 1 year, 40 funds have data · LHLONGEVITY has no data for this period yet
กองทุนมีนโยบายลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศ (หรือ “กองทุนหลัก (Master fund)”) ที่มีนโยบายลงทุนในตราสารทุน โดยจะลงทุนในหน่วยลงทุนของกองทุนหลักโดยเฉลี่ยในรอบปีบัญชีไม่น้อยกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิของกองทุน ซึ่งกองทุนไทยจะลงทุนในหน่วยลงทุนของกองทุน Tema Oncology ETF… Its largest holdings are Revolution Medicines Inc 6.02% · Eli Lilly & Co 5.15% · Cogent Biosciences Inc 4.70% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 26 Mar 2026, its NAV has fallen as much as −11.95% from its peak.
Actual total expense ratio (TER) 2.10% a year, against a ceiling of 5.00%. Management fee 1.60%. Front-end fee 1.61%. Back-end fee 0.00%. (Fact sheet 30 Sep 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase 1,000 THB, subsequent purchases 100 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+2
Hedged at the manager's discretion. As of 30 Sep 2026, 79.91% of the value of its foreign investments was hedged
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Cogent Biosciences COGT4.67%
Eli Lilly and Co LLY4.51%
Novartis AG Registered Shares NOVN.SW3.64%
Bristol-Myers Squibb Co BMY3.41%
BeOne Medicines Ltd ADR ONC3.31%
Iovance Biotherapeutics IOVA3.29%
ABBVIE ABBV3.27%
Genmab AS ADR GMAB3.17%Revolution Medicines RVMDBiotech company that develops drugs for RAS-driven cancers, such as pancreatic cancer
Merck & MRKHospitals, medicines and medical equipment
Cogent Biosciences COGTHospitals, medicines and medical equipment
Eli Lilly and Co LLYDiabetes and weight-loss drugs
Novartis AG Registered Shares NOVN.SWHospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
ABBVIE ABBVHospitals, medicines and medical equipment
Genmab AS ADR GMABBased on the master fund's share of this fund's value (98.94% as of 30 Sep 2026) × each stock's weight in the master fund · stocks as of 20 Oct 2026 · Illustrations are for explanation only, not individual stock recommendations